Welcome to our dedicated page for Pluri news (Ticker: PLUR), a resource for investors and traders seeking the latest updates and insights on Pluri stock.
Pluri Inc. develops cell-based technologies built around its proprietary 3D cell expansion platform. Company news commonly covers mass-scale cell expansion, biofarming, regenerative medicine applications, immune-cell manufacturing intellectual property, and the use of PluriCDMO™ for contract development and manufacturing programs involving cell-derived therapeutics, biologics, and placenta-derived biomaterials.
Recurring updates also address Pluri’s venture and subsidiary activity across foodtech, agtech, and health and aesthetics, including Coffeesai, Ever After Foods, Kokomodo, and Cellav. Additional news themes include commercial collaborations, patent grants, board and governance changes, private placements, and other capital actions tied to Pluri’s platform, subsidiaries, and public-company structure.
Pluri Inc. launched a novel immunotherapy platform for solid tumor cancer treatment utilizing placental MAIT cells, a unique type of immune cells with great potential. Pluri's proprietary technology overcomes challenges in expanding MAIT cells, offering advantages over conventional T cells. The global cancer immunotherapy market is projected to reach $275.11 billion by 2032. Renowned cancer researchers Dr. Prasad S. Adusumilli and Dr. Richard L. Kendall joined Pluri's Scientific Advisory Board to support this groundbreaking platform.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.